Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report January – March 2022

First quarter 2022• Net sales increased to SEK 3,779m (3,373) corresponding to organic sales growth of 6% (3).• Operating profit decreased to SEK 182m (196), corresponding to an operating margin of 4.8% (5.8).• Changes in exchange rates positively impacted operating profit by SEK 30m.• Profit after tax amounted to SEK 128m (132), corresponding to earnings per share before and after dilution of SEK 0.76 (0.78).• Operating cash flow amounted to SEK -420m (-69), of which -263m (-9) was related to investments in the new Nordic factory.• Superfront was acquired.• Adjusted segment

Interim Report 1 January–31 March 2022

We have put yet another turbulent quarter behind us following the reintroduction of restrictions at the end of last year, which were made even more stringent in the beginning of January. Consequently, the majority of our arenas had to postpone their seasonal opening, while the demand for tickets for upcoming periods declined. However, we are pleased to note that since being allowed to reopen all of our operations at the end of February, we have enjoyed good seat occupancy, especially for our major productions, and strong demand in our two event companies, while most of the other operations

Interim report, 1 January–31 March 2022

Stronger product tanker market · Total income Q1:SEK 124.1 (179.6) million  · EBITDA Q1:SEK 29.7 (–45.7) million  · Result before tax Q1:SEK –30.4 (–120.2) million  · Result per share after tax Q1:SEK –0.64 (–2.54) Events in the first quarter · Sale of two P-MAX vessels · P-MAX vessel Stena Polaris chartered out · Technical design study for possible container conversion launched · New long-term financial covenant terms Events after the end of the quarter · No significant events occurred after the end of the quarter. Key figures

Q1 2022: NORDEN WITH STRONG START TO THE YEAR

ANNOUNCEMENT NO. 111 - 5 MAY 2022 For the first quarter of 2022, NORDEN reports a profit of USD 117 million (Q1 2021: USD -15 million). NORDEN CEO, Jan Rindbo, comments: “Great Q1 result based on strong performances in both business units as we continue to capture value in the dry cargo market through vessel sales, profitable cover and by utilising regional market volatility. By shifting our market exposure from dry cargo to tankers, combined with excellent vessel positioning towards a much-improved tanker market in recent weeks, NORDEN expects a full-year result between USD 270-

3 new companies to present at the BioStock Life Science Spring Summit on June 8-9!

On June 8-9, it is finally time for BioStock Life Science Spring Summit 2022, where companies from a wide range of therapeutic areas will present their projects and innovations, in a packed program that also offers valuable insights from investment experts and industry profiles. Today, we reveal three new companies that will present at the Summit!The event will be broadcasted on the BioStock website and on our YouTube channel. You can also access the event through our social media platforms. Today we reveal three new companies that will present at the BioStock Life Science Spring Summit

Nordea cancels repurchased shares

Nordea Bank AbpStock exchange release – Total number of voting rights and capital5 May 2022 at 9.15 EET Nordea Bank Abp (“Nordea”) has today cancelled 49,243,777 treasury shares, which were held for capital optimisation purposes and acquired through share buy-backs, in line with the decision by the Board of Directors. The cancellation of the treasury shares has been registered with the Finnish Trade Register on 5 May 2022. After the cancellation, the total number of shares in Nordea is 3,789,514,793 and the total number of votes attached to the shares is 3,789,514,793. Nordea

Change in Pihlajalinna Plc’s Management Team

Pihlajalinna Plc Stock exchange release  5 May 2022 at 9.10 a.m.   Change in Pihlajalinna Plc’s Management Team   Pihlajalinna is planning the renewal of its operating structure and a transition to an organisational structure based on business activities. The renewal of the operating structure would also lead to a change in Pihlajalinna’s segment reporting. Going forward, the operating segments would be the company’s two business segments: Public Services, and Private Clinic and Hospital Services.Pihlajalinna Group has appointed Eetu Salunen, Licentiate of Medicine and Master

Invitation to presentation of Interim Report January 1 – March 31, 2022

Mekonomen’s Interim Report for the first quarter 2022 will be published on Wednesday 11 May at 07:30 a.m CEST. A webcast/telephone conference will be held on the same day at 09:00 a.m CEST in English. Mekonomen's President and CEO Pehr Oscarson and CFO Åsa Källenius will present the results and respond to questions at the English speaking conference. The presentation material will be available from 8:00 a.m CEST on 11 May, at www.mekonomen.com under the heading Investors/IR Presentations.  

Enhertu approved in US for 2L HER2+ breast cancer

05 May 2022 07:10 BST Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu to earlier use in metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results showing Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or

Interim Report First Quarter 2022

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2022 – 31.03.2022. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:When we look back on Q1 2022 it was gratifying to see the hard work of 2021 successfully completed: We had a medical cannabis oil product approved for Denmark, we entered the UK market with three approved

BioStock: Sprint Bioscience launches NIMA at BIO International

It has been a little more than six months since Huddinge-based Sprint Bioscience announced its latest development project NIMA. Now the company chooses to shed some more light on the program, revealing the the target protein. The official launch will be at BIO International, which this year will be held in San Diego June 13-16. BioStock contacted Martin Andersson, CSO at Sprint Bioscience, to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-launches-nima-at-bio-international/This is a press release from BioStock - Connecting

Farxiga HFpEF Phase III trial met primary endpoint

5 May 2022 07:05 BST Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Results from the DELIVER and DAPA-HF Phase III trials demonstrate Farxiga's efficacy in heart failure regardless of ejection fraction High-level results from the DELIVER Phase III trial showed AstraZeneca's Farxiga (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

Ultomiris NMOSD Ph. III trial met primary endpoint

5 May 2022 07:00 BST Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder Zero adjudicated relapses observed among Ultomiris patients over a median treatment duration of 73 weeks   Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) compared to the

Aiforia Technologies Plc appoints Vice President of Sales for Europe

Aiforia Technologies Plc, Press Release, 5 May 2022 at 09.00 a.m. EEST. Incoming Vice President joins Aiforia from global market leader in digital pathology devices, 3DHISTECH, bringing with him decades of experience holding various executive positions in sales at other companies such as Cisco and Ericsson.Aiforia has appointed Tamas Regenyi as Vice President of Sales, Europe. The position will be essential to driving Aiforia’s business strategy in the region; focusing on accelerating growth in Aiforia’s established preclinical market in acquiring large customers in the pharmaceutical

AutoStore: Reminder - invitation to presentation of first quarter 2022 financial results

(Oslo, 5 May 2022): AutoStore Holdings Ltd (AutoStore: OSE:AUTO) invites investors, analysts and journalists to join the presentation of the first quarter 2022 financial results on Thursday 12 May 2022 at 08:00 CEST via a live webcast and conference call.06:00 - Announcement of first quarter 2022 financial results. All material will be made available on newsweb.no and www.autostoresystem.com. 08:00 - Presentation will be held only via live webcast and conference call. The presentation will be hosted by Karl Johan Lier, CEO, Bent Skisaker, CFO, and Mats Hovland Vikse, CRO. It will be

Citycon among Financial Times’ European Climate Leaders for the second consecutive year

CITYCON OYJ Corporate Press Release 5 May 2022 Citycon is among Europe’s Climate Leader companies according to Financial Times and German research company Statista. Citycon is the only Finnish real estate company included on the list and is in the top quarter of all European companies regardless of the sector. “We are proud to be recognized among the Climate Leaders for the second consecutive year. This acknowledgement provides evidence of the hard work done by Cityconners to implement targeted measures to reduce greenhouse gas emissions”, says F. Scott Ball, the Chief

Metsä Group awarded as Finland’s most startup-friendly company in 2021

Metsä Group press release 5 May 2022Metsä Group has been selected as the most startup-friendly company in Finland in 2021. The award is presented by the entrepreneurial and startup community Tribe Tampere. "Metsä Group has actively developed its cooperation with the startup field, most concretely by establishing the innovation company Metsä Spring about four years ago. We are very grateful and proud that our determined contribution has led to this recognition,” says Erik Kolehmainen, who is responsible for Corporate Venturing operations at Metsä Group. Selection criteria for the award

DDM Holding AG and DDM Debt AB to report first quarter 2022

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM Debt 2026) will publish their Q1 2022 reports on Thursday 19 May 2022 at 08:00 CEST. Mr. Florian Nowotny, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CEST, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 566 427 06Switzerland: +41 225 805

DDM Holding AG and DDM Debt AB to report first quarter 2022

DDM Holding AG (First North Growth Market: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM Debt 2026) will publish their Q1 2022 reports on Thursday 19 May 2022 at 08:00 CEST. Mr. Florian Nowotny, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 CEST, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 566 427 06Switzerland: +41 225 805

I-Tech AB (publ) Interim report Q1 2022

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the first quarter 2022 Click here on the 5 May 2022 at 10:30 to follow the webcast  Click here to go to I-Tech's Financial Reports Summary of the period ” Increased profit and improved profitability in a quarter with unchanged net sales ” • Net turnover for the first quarter amounted to 14 478 (14 458) kSEK, corresponding to an increase in turnover of 0% (7%). Operating profit/loss amounted to 333 (58) kSEK.

Interim report Q1 2022

Growth despite challenging conditionsFirst quarter, January-March, 2022 · Operating revenue was SEK 2,147 million (1,986), an increase of 8.1 percent, which is mainly explained by acquisitions, previously opened units within Elderly Care, and strong growth in Norway. · Organic growth was 1.8 percent (2.4). Organic growth was driven by Elderly Care and Norway, but growth was slowed down by lower occupancy and closed units within Individual and Family. · Operating profit amounted to SEK 77m (112), a decline of 31.9 percent. The decrease is partly explained by externally related

AcadeMedia’s interim report July 2021 – March 2022

Third quarter (January – March 2022) · Net sales increased by 5.9 percent and amounted to SEK 3,802 million (3,591). Organic growth, including bolt-on acquisitions, was 4.7 percent. · Operating profit (EBIT) amounted to SEK 313 million (346). · Adjusted operating profit, adjusted for items affecting comparability and effects of IFRS 16, amounted to SEK 264 million (279). Items affecting comparability amounted to SEK -27 million (6) and related to a fire in a compulsory school in the first quarter and restructuring expenses in the Upper Secondary School Segment. · Net profit

Finnair Traffic Performance in April 2022

Finnair Plc                Investor News              5 May 2022 at 9:00 a.m. EEST Clear improvement in April passenger traffic figures year-on-year and even month-on-month despite the Russian airspace closure; cargo figures remain strong In April, Finnair carried 680,300 passengers, which was 740.4% more than in April 2021. The number of passengers in April 2022 was 10.7% more than in March 2022 (month-on-month figures are not fully comparable as there was one fewer day in April). The COVID-19 impact, including the strict travel restrictions imposed by several countries due to the

Bioretec has submitted a market authorization request for its bioresorbable RemeOs™ magnesium screw in the U.S.

Bioretec Ltd    Company Announcement      5 May 2022 at 9.00 a.m. EEST INSIDE INFORMATIONBioretec Ltd, a pioneer in bioresorbable orthopedic implants, has submitted a De Novo request for market authorization in the United States for the RemeOs™ trauma screw based on bioresorbable magnesium alloy. Bioretec estimates the market authorization in the United States to be granted during the second half of 2022. The previously communicated estimate was in the first half of 2022. The De Novo request provides a registration pathway for novel medical devices for which there is no predicate

There are no items matching the current filter
There are no more items matching the current filter
Back to top